Retroperitoneal leiomyosarcoma

Summary

Retroperitoneal leiomyosarcoma (MONDO:0003370) is a disease and 1 clinical trial. A subtype of retroperitoneal sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	retroperitoneal leiomyosarcoma
Mondo ID	MONDO:0003370
DOID	DOID:5284
NCIT	C27904
UMLS	C2187547
MedGen	412162
GARD	0023483
Anatomy (UBERON)	UBERON:0003693
Is cancer (heuristic)	no

Also known as: leiomyosarcoma of retroperitoneal space · retroperitoneal leiomyosarcoma · retroperitoneal space leiomyosarcoma

Data availability: 5 cell lines.

Disease family

This is a subtype of retroperitoneal sarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › retroperitoneal cancer › retroperitoneal sarcoma › retroperitoneal leiomyosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02587169	PHASE1/PHASE2	UNKNOWN	Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum